real-time news and commentary for investors
Thursday, Oct 18
2012, 4:38 PM
More on Cepheid (CPHD): Q3 beats on a per share basis with revenue largely in-line with...
More on Cepheid (CPHD): Q3 beats on a per share basis with revenue largely in-line with estimates. Net losses were $21.3M, or -$0.32 per share, largely due to litigation settlement charges. Results were also affected by a buildup in back orders due to intermittent interruption in availability of certain plastic parts used in the production of its Xpert cartridges, which prevented the fulfillment of all test cartridge orders in the quarter.